Overview
Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response
Status:
Completed
Completed
Trial end date:
2011-06-01
2011-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
A research study to measure the effect on CD4 counts of adding to current anti-retroviral regimen raltegravir with or without hyper-immune bovine colostrum.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Kirby InstituteTreatments:
Raltegravir Potassium
Criteria
Inclusion Criteria:- Documented HIV-1 infection
- Age >18 years
- Signed informed consent
- Receiving combination ART (cART) for at least 12 months with a stable cART regimen for
a minimum of 6 months. A formulation change or modification of dosage schedule is
acceptable (for example ritonavir - boosted lopinavir capsules for tablets, abacavir
(ABC) or tenofovir (TDF) and lamivudine (3TC) or emtricitabine (FTC) as single agents
for ABC/3TC or TDF/FTC fixed dose combinations)
- Two consecutive plasma HIV RNA viral load measurements <50 (or <400 copies/mL
depending upon lowest level of detection of the local assay) in the 9 months preceding
the screening visit. A single isolated HIV RNA viral load >50 (or >400) copies/mL will
not exclude the patient provided the viral load result >50 (or 400) copies/mL on
therapy follows a previous result <50 (or 400) copies/mL, and there is a follow-up
result <50 copies/mL at least one week following the >50 (or 400) copies/mL reading in
the absence of a change to any component of the ART regimen.
- CD4+ T cell count <350 cells/µL throughout the 6 months preceding the screening visit
with <50 cells/µL increase in the last 12 months
Exclusion Criteria:
- Receiving a cART regimen containing an integrase inhibitor
- Anticipated change of cART in the 24 weeks following randomisation
- Participating in study with an investigational compound or device within 30 days of
signing informed consent
- Use of immune modulating therapies or immunosuppressive medications within 60 days
prior to study entry. Patients using inhaled or nasal steroids are not excluded
- Pregnant or breastfeeding woman
- Cow's milk allergy
- Concurrent treatment with phenobarbitol, phenytoin or rifampicin.
- A known cause of impaired CD4+ T cell gain: for example, patients with splenomegaly or
individuals whose current cART regimen contains both tenofovir and didanosine